Compare Cytokinetics Inc (CYTK) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Logitech International SA — how do they compare? Cytokinetics Inc trades at $62.76 (market cap $8.62B), while Logitech International SA trades at $98.36 (market cap $14.46B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.63% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Logitech International SA for 92 Days on average.
| CYTK | LOGI | |
|---|---|---|
Market Cap | $8.62B | $14.46B |
Volume | 2,594,626 | 349,547 |
Sector | Health | Technology |
52-Week High | $87.26 | $126.69 |
52-Week Low | $54.76 | $85.84 |
Typical Hold Time | 19 Days | 92 Days |
Enterprise Value | $8.72B | $12.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Logitech (LOGI) trades at $100.70, down 1.45% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.85 surpassing the $1.26 estimate. The company maintains strong profitability, including a 16.28% net income margin and 35.29% ROE, and has announced new product launches like the Zone Vibe Pro headset and a partnership with SEGA.
The outlook is supported by solid fundamentals and positive product news, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is mixed, with a Hold consensus, suggesting cautious optimism. Upside potential exists if the company continues its earnings beat streak and navigates supply chain challenges effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
